Drug Trial Radar · NCT06833749
Efficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis
Last checked: Nov 19, 2026Latest source record: Feb 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Jan 28, 2025
Primary completion
Nov 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- KeyBioscience AGIndustry
- Sponsor type
- Industry
- First posted
- Feb 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if KBP-336 works to treat pain in osteoarthritis in individuals living with obesity. It will also learn about the effects on other parameters, such as quality of life and metabolism, as well as safety of KBP-336. The main questions it aims to answer are: * Does KBP-336 lower knee pain from osteoarthritis in individuals with obesity * Does KBP-336 lower bodyweight in the same population. Researchers will compare KBP-336 to a placebo (a look-alike substance that contains no drug) to see if KBP-336 works to pain and obesity Participants will: * Take KBP-336 or a placebo every week for 6 months * Visit the clinic once every 2 weeks for checkups and tests * Keep a diary of their symptoms and the amount of medication they use in addition to KBP-336
Conditions
- Osteoarthritis in the Knee
- Obesity
Interventions
KBP-336Drug
KBP-336 is a long acting Dual Amylin and Calcitonin Receptor agonist designed for weekly administration through subcutaneous injection.
PlaceboDrug
Placebo to match KBP-336
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportional change in body weight from baseline to endpointTime frame: 183 Days
- The change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain scale from baseline to endpointTime frame: 183 Days
Locations
20 sites in 6 countries. Site status is shown where the registry gives one.
Pratia Brno, s.r.o
Brno, Czechia · Not yet recruiting
L.K.N. Artrocentrum
Hlučín, Czechia · Not yet recruiting
Medical Plus, s.r.o
Hradiště, Czechia · Not yet recruiting
Pratia Pardubice a.s.
Pardubice, Czechia · Not yet recruiting
Affidea Praha s.r.o
Prague, Czechia · Not yet recruiting
Pratia Prague, s.r.o
Prague, Czechia · Not yet recruiting
Sanos Clinic Nordjylland
Gandrup, Denmark · Recruiting
Sanos Clinic Herlev
Herlev, Denmark · Recruiting
Sanos Clinic Syddanmark
Vejle, Denmark · Recruiting
Hong Kong Center for Clinical Research
Hong Kong, Hong Kong · Not yet recruiting
IMSP Sptalul Clinic Municipal "Sfanta Treime"
Chisinau, Moldova · Not yet recruiting
PMSI Cardiology Institute/RTL SM SRL
Chisinau, Moldova · Not yet recruiting
Timofei Mosneaga Republican Clinical Hospital
Chisinau, Moldova · Not yet recruiting
NZOZ Bif-Med. s.c.
Bytom, Poland · Not yet recruiting
Medyczne Centrum Hetmańska
Poznan, Poland · Not yet recruiting
DC-MED SP z o.o.
Swidnica, Poland · Not yet recruiting
NZOZ Lecznica MAK-MED s.c.
Warsaw, Poland · Not yet recruiting
Migre Polskie Centrum Leczenia Migreny
Wroclaw, Poland · Not yet recruiting
Policlinica CCBR
Bucharest, Romania · Not yet recruiting
Quantum Medical Bucharest
Bucharest, Romania · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.